Literature DB >> 28402928

Management of Advanced Fibrosis in the Context of Hepatitis C Virus Infection.

Elizabeth C Verna1.   

Abstract

Advanced fibrosis may be present in a substantial proportion of individuals with asymptomatic, chronic hepatitis C virus (HCV) infection, including those who have been newly diagnosed. HCV treatment improves all-cause and liver-related mortality in individuals with advanced fibrosis, and there is some evidence that reversal of decompensated liver disease may occur in those with a sustained virologic response. HCV treatment is also crucial for individuals undergoing liver transplantation, as recurrent HCV infection posttransplantation is associated with accelerated fibrosis progression and increased risk of poor outcomes. This article summarizes a presentation by Elizabeth C. Verna, MD, at the IAS-USA continuing education program, Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes, held in New York, New York, in September 2015.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28402928      PMCID: PMC5677038     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  11 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

2.  Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.

Authors:  K Rajender Reddy; Marc Bourlière; Mark Sulkowski; Masao Omata; Stefan Zeuzem; Jordan J Feld; Eric Lawitz; Patrick Marcellin; Tania M Welzel; Robert Hyland; Xiao Ding; Jenny Yang; Steven Knox; Phillip Pang; Hadas Dvory-Sobol; G Mani Subramanian; William Symonds; John G McHutchison; Alessandra Mangia; Edward Gane; Masashi Mizokami; Stanislas Pol; Nezam Afdhal
Journal:  Hepatology       Date:  2015-05-09       Impact factor: 17.425

3.  Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Authors:  Michael P Curry; Xavier Forns; Raymond T Chung; Norah A Terrault; Robert Brown; Jonathan M Fenkel; Fredric Gordon; Jacqueline O'Leary; Alexander Kuo; Thomas Schiano; Gregory Everson; Eugene Schiff; Alex Befeler; Edward Gane; Sammy Saab; John G McHutchison; G Mani Subramanian; William T Symonds; Jill Denning; Lindsay McNair; Sarah Arterburn; Evguenia Svarovskaia; Dilip Moonka; Nezam Afdhal
Journal:  Gastroenterology       Date:  2014-09-28       Impact factor: 22.682

4.  Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.

Authors:  Josh Levitsky; Elizabeth C Verna; Jacqueline G O'Leary; Natalie H Bzowej; Dilip K Moonka; Robert H Hyland; Sarah Arterburn; Hadas Dvory-Sobol; Diana M Brainard; John G McHutchison; Norah A Terrault
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

5.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

6.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

7.  A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Authors:  Jules L Dienstag; Marc G Ghany; Timothy R Morgan; Adrian M Di Bisceglie; Herbert L Bonkovsky; Hae-Young Kim; Leonard B Seeff; Gyongyi Szabo; Elizabeth C Wright; Richard K Sterling; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S Lok; Chihiro Morishima; Anne M Stoddard; James E Everhart
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

8.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.